Keros Therapeutics Inc — Quarterly Cash Flow (NASDAQ:KROS) | MetaTrader

Open full chart

Financials

Overview Relevé Statistics

Quarterly Annual

Total assets 615.89 M784.56 M757.16 M742.78 M338.02 M Total liabilities 44.33 M55.69 M50.43 M39.2 M34.89 M Total equity 571.55 M728.87 M706.73 M703.58 M303.13 M Total liabilities & shareholders' equities 615.89 M784.56 M757.16 M742.78 M338.02 M Total debt ————— Net debt —————

Nouvelles

Insmed (INSM) Soars 5.5%: Is Further Upside Left in the Stock?

KROS: Is the Discount Book Value a Value Trap?

KROS Stock: What to Know About Rinvatercept in DMD

KROS Pipeline Catalysts: DMD Phase II and ALS Plans for 2026

Can Keros Therapeutics Rinvatercept Stand Out in the DMD Market?

Can Reblozyl Stabilize BMY's Top Line Amid Legacy Drugs Decline?

Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates

Le BPA de Keros a manqué les attentes de 0,16$, le CA en dessous des prévisions

Keros earnings missed by $0.16, revenue fell short of estimates

Should Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings?

Will Reblozyl Shine in Bristol Myers' Fourth-Quarter Results?

SRPT Stock Up 8% on Positive Long-Term Data From Elevidys Study in DMD